Merck KGaA · XETR:MRK
Merck KGaA — Investor Day (September 2021)
9 slides from Merck KGaA's investor day presentation, Sep 9, 2021
Slide 1: Healthcare: Evolution towards focused leadership
Healthcare Evolution towards focused leadership Peter Guenter, CEO Healthcare 2nd Virtual Merck CMD – September 9, 2021
Slide 2: Disclaimer
Disclaimer Cautionary Note Regarding Forward-Looking Statements and financial indicators This communication may include “forward-looking statements.” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and other wor
Slide 3: Well positioned to deliver significant long-term growth
Classification: Public Healthcare Well positioned to deliver significant long-term growth Early- to mid-stage pipeline NRA Healthy risk profile Xevinapant Cis-ineligible NRA Xevinapant Cis-eligible NRA Evobrutinib BTKi NRA Resilience of our commercialized Recent Launches products1 across all TAs Est
Slide 4: Strengthening our leadership in Fertility
Healthcare Strengthening our leadership in Fertility Global Gonadotropin market in € bn 1 Strategies to expand our leadership position GONAL-f The world’s most prescribed r-hFSH treatment3 +6,4% 2,4 ▪ Growing prevalence of infertility driven by delayed 2,3 2,2 parenthood and lifestyle habits 2,0 ▪ I
Slide 5: Evobrutinib
Healthcare Pioneering patient benefit in MS for > 30 years Evobrutinib BTKi ▪ Designed for best-in-class efficacy5 ▪ Full covalent binding and dosing regimen expected to enable ▪ Oral high-efficacy therapy with unique constant, near complete BTK posology & mode of action2,3 occupancy6 ▪ Blockbuster
Slide 6: Building focused leadership positions in Oncology
Healthcare Building focused leadership positions in Oncology 1 Building leadership in mUC Defining leadership Expanding leadership in MET-driven tumors in SCCHN ▪ Bavencio redefined SoC in mUC with ▪ Tepmetko - discovered and ▪ Xevinapant5 focuses on a novel unique 1L maintenance Tx. Since developed
Slide 7: Strong innovation potential in key areas to secure long-term growth
Healthcare Strong innovation potential in key areas to secure long-term growth Research & Early Development Mid- to Late-Stage Development Industry-leading capabilities in Targeting attractive opportunities Blockbuster opportunities key platforms and disease pathways in Oncology & Immunology with at
Slide 8: Meet Merck Management
Meet Merck Management Speakers in Healthcare deep dive Q&A Peter Guenter Joern-Peter Halle Chris Round CEO Healthcare Head of Research Head of North America Danny Bar-Zohar Andrew Paterson Andreas Stickler Head of Development Chief Marketing Officer Head of Healthcare Controlling, Strategy and Busin
Slide 9: Investor Relations contacts
CONSTANTIN FEST SVENJA DJAVAHERI SARA HOFMANN Head of Investor Relations Assistant Investor Relations Assistant Investor Relations +49 6151 72-5271 +49 6151 72-3744 +49 6151 72-3321 constantin.fest@merckgroup.com svenja.djavaheri@merckgroup.com sara.hofmann@merckgroup.com ILJA DOERING GUNNAR ROMER A